Share This:
https://ntp.niehs.nih.gov/go/16832

TDMS Study 96022-02 Pathology Tables

NTP Experiment-Test: 96022-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                            TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118)                       Date: 04/27/04
Route: GAVAGE                                                                                                     Time: 13:08:23

                                                      31 WEEK SSAC/FINAL#1




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  TEFPCBMIX

       Lock Date:  11/04/02

       Cage Range:  All

       Reasons For Removal:    25017 Scheduled Sacrifice

       Removal Date Range:     05/16/00 - 05/17/00

       Treatment Groups:       Include 001    0 NG /  0 UG
                               Include 002    80 NG  /10 UG
                               Include 003    240 NG /30 UG
                               Include 004    800 NG /100 UG
                               Include 005    2400 NG/300 UG
                               Include 006    4000 NG/500 UG





























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96022-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                            TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118)                       Date: 04/27/04    
Route: GAVAGE                                                                                                     Time: 13:08:23    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       80 NG  /     240 NG /     800 NG /     2400 NG/     4000 NG/        
                                                   0 UG         10 UG        30 UG        100 UG       300 UG       500 UG          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          98           86           98           86           98           86           
                                                                                                                                    
  Scheduled Sacrifice                                 16           10           16           10           16           10           
  Early Deaths                                                                                                                      
  Survivors                                                                                                                         
                                                                                                                                    
  Animals Examined Microscopically                    10           10           10           10           10           10           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (10)         (10)         (10)         (10)         (10)         (10)         
      Basophilic Focus                                 1 (10%)                                                                      
      Cholangiofibrosis                                1 (10%)                                2 (20%)      2 (20%)      1 (10%)     
      Eosinophilic Focus                                                                                   3 (30%)      2 (20%)     
      Eosinophilic Focus, Multiple                                                                         4 (40%)      3 (30%)     
      Fatty Change, Diffuse                                                                   3 (30%)      8 (80%)      9 (90%)     
      Hepatodiaphragmatic Nodule                       1 (10%)                                1 (10%)                               
      Hyperplasia, Nodular                                                                                 1 (10%)      4 (40%)     
      Infarct                                                                                              1 (10%)                  
      Inflammation                                    10 (100%)    10 (100%)    10 (100%)    10 (100%)    10 (100%)    10 (100%)    
      Mixed Cell Focus                                 3 (30%)      5 (50%)      1 (10%)                                            
      Mixed Cell Focus, Multiple                       2 (20%)      3 (30%)      1 (10%)      6 (60%)                               
      Necrosis                                         1 (10%)      1 (10%)      1 (10%)                   2 (20%)                  
      Pigmentation                                     2 (20%)      4 (40%)      9 (90%)     10 (100%)    10 (100%)    10 (100%)    
      Toxic Hepatopathy                                                                       3 (30%)     10 (100%)    10 (100%)    
      Bile Duct, Fibrosis                              1 (10%)                                1 (10%)                               
      Bile Duct, Hyperplasia                                                                  1 (10%)     10 (100%)    10 (100%)    
      Centrilobular, Fibrosis                                                                 3 (30%)     10 (100%)    10 (100%)    
      Hepatocyte, Hypertrophy                                       2 (20%)      4 (40%)      8 (80%)     10 (100%)    10 (100%)    
      Hepatocyte, Multinucleated                                                              3 (30%)     10 (100%)    10 (100%)    
      Oval Cell, Hyperplasia                                                                               8 (80%)     10 (100%)    
      Portal, Fibrosis                                                                                     1 (10%)      4 (40%)     
   Pancreas                                           (10)         (10)         (10)         (10)         (10)         (10)         
      Inflammation, Chronic Active                                                                                      2 (20%)     
      Acinus, Atrophy                                                                                      1 (10%)      2 (20%)     
      Acinus, Vacuolization Cytoplasmic                                                       1 (10%)     10 (100%)    10 (100%)    
   Stomach, Forestomach                               (10)                      (1)                                    (10)         
      Serosa, Inflammation, Chronic Active                                       1 (100%)                                           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 96022-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                            TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118)                       Date: 04/27/04    
Route: GAVAGE                                                                                                     Time: 13:08:23    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       80 NG  /     240 NG /     800 NG /     2400 NG/     4000 NG/        
                                                   0 UG         10 UG        30 UG        100 UG       300 UG       500 UG          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (10)         (10)         (10)         (10)         (10)         (10)         
      Angiectasis                                                   6 (60%)      2 (20%)                   1 (10%)      1 (10%)     
      Atrophy                                                                                              2 (20%)      8 (80%)     
      Degeneration, Cystic                                          1 (10%)                                                         
      Hypertrophy                                      5 (50%)      4 (40%)      3 (30%)      3 (30%)      3 (30%)      1 (10%)     
   Pituitary Gland                                    (10)         (1)                                                 (10)         
      Angiectasis                                                   1 (100%)                                                        
      Cyst                                             1 (10%)                                                          1 (10%)     
      Cytoplasmic Alteration                                                                                            1 (10%)     
   Thyroid Gland                                      (10)         (10)         (10)         (10)         (10)         (10)         
      Inflammation, Chronic Active                                                                                      1 (10%)     
      Follicular Cell, Hypertrophy                     3 (30%)      3 (30%)      7 (70%)      7 (70%)      9 (90%)      7 (70%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (10)         (10)         (10)         (10)         (10)         (10)         
      Atrophy                                          6 (60%)      7 (70%)      7 (70%)      4 (40%)      1 (10%)                  
   Uterus                                             (10)         (10)         (10)         (10)         (10)         (10)         
      Decidual Reaction                                                          1 (10%)                                            
      Inflammation, Suppurative                        1 (10%)                                                                      
      Metaplasia, Squamous                             5 (50%)      6 (60%)      6 (60%)      4 (40%)      1 (10%)                  
      Endometrium, Hyperplasia, Cystic                 5 (50%)      5 (50%)      6 (60%)      3 (30%)      1 (10%)      1 (10%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Spleen                                             (10)                                                             (10)         
      Pigmentation                                    10 (100%)                                                        10 (100%)    
   Thymus                                             (10)         (10)         (10)         (9)          (10)         (6)          
      Atrophy                                          3 (30%)      2 (20%)      5 (50%)      9 (100%)     9 (90%)      6 (100%)    
      Cyst                                                                                    1 (11%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 96022-02         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                            TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118)                       Date: 04/27/04    
Route: GAVAGE                                                                                                     Time: 13:08:23    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       80 NG  /     240 NG /     800 NG /     2400 NG/     4000 NG/        
                                                   0 UG         10 UG        30 UG        100 UG       300 UG       500 UG          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (10)                                                             (10)         
      Hyperplasia                                      2 (20%)                                                                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (10)         (10)         (10)         (10)         (10)         (10)         
      Hemorrhage                                       2 (20%)                                1 (10%)      1 (10%)                  
      Infiltration Cellular, Histiocyte                3 (30%)      2 (20%)      4 (40%)      2 (20%)      5 (50%)      2 (20%)     
      Inflammation                                                  1 (10%)                                                         
      Inflammation, Granulomatous                                                             1 (10%)      2 (20%)      2 (20%)     
      Metaplasia, Squamous                                                                                              1 (10%)     
      Alveolar Epithelium, Hyperplasia                                                                                  1 (10%)     
      Alveolar Epithelium, Metaplasia, Bronchiolar                                                         3 (30%)      3 (30%)     
      Interstitium, Fibrosis, Focal                                                                        1 (10%)                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------